In the volatile world of biotech, few companies manage to combine rapid growth with a path toward sustainable profitability. Yet TG Therapeutics (NASDAQ:TGTX) appears to be doing exactly that. Its Q3 2025 results show a major revenue jump, a big swing in earnings per share, and a renewed sense of confidence from analysts. For investors, TG Therapeutics could represent a rare growth at a reasonable price opportunity. In this article we will dive into TG Therapeutics recent earnings, stock performance & valuation, growth potential, and the risks investor should consider.
Seeking Undervalued Stocks With Great Future Growth in the US Stock Market